242 related articles for article (PubMed ID: 25933930)
1. Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer.
Rosenberg SM; Stanton AL; Petrie KJ; Partridge AH
Oncologist; 2015 Jun; 20(6):598-604. PubMed ID: 25933930
[TBL] [Abstract][Full Text] [Related]
2. Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry.
Stanton AL; Petrie KJ; Partridge AH
Breast Cancer Res Treat; 2014 Jun; 145(2):525-34. PubMed ID: 24781972
[TBL] [Abstract][Full Text] [Related]
3. Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer.
Walker HE; Rosenberg SM; Stanton AL; Petrie KJ; Partridge AH
J Adolesc Young Adult Oncol; 2016 Mar; 5(1):16-23. PubMed ID: 26812461
[TBL] [Abstract][Full Text] [Related]
4. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors.
Breckenridge LM; Bruns GL; Todd BL; Feuerstein M
Psychooncology; 2012 Jan; 21(1):43-53. PubMed ID: 20967847
[TBL] [Abstract][Full Text] [Related]
5. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
6. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.
Frechette D; Paquet L; Verma S; Clemons M; Wheatley-Price P; Gertler SZ; Song X; Graham N; Dent S
Breast Cancer Res Treat; 2013 Aug; 141(1):111-7. PubMed ID: 23942873
[TBL] [Abstract][Full Text] [Related]
7. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
[TBL] [Abstract][Full Text] [Related]
9. Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study.
Nestoriuc Y; von Blanckenburg P; Schuricht F; Barsky AJ; Hadji P; Albert US; Rief W
Ann Oncol; 2016 Oct; 27(10):1909-15. PubMed ID: 27551051
[TBL] [Abstract][Full Text] [Related]
10. Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study.
Ganz PA; Petersen L; Bower JE; Crespi CM
J Clin Oncol; 2016 Mar; 34(8):816-24. PubMed ID: 26786934
[TBL] [Abstract][Full Text] [Related]
11. Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.
Graetz I; McKillop CN; Stepanski E; Vidal GA; Anderson JN; Schwartzberg LS
J Cancer Surviv; 2018 Aug; 12(4):431-440. PubMed ID: 29492753
[TBL] [Abstract][Full Text] [Related]
12. Beliefs about medicine and illness are associated with fear of cancer recurrence in women taking adjuvant endocrine therapy for breast cancer.
Corter AL; Findlay M; Broom R; Porter D; Petrie KJ
Br J Health Psychol; 2013 Feb; 18(1):168-81. PubMed ID: 23134580
[TBL] [Abstract][Full Text] [Related]
13. Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer.
Boele FW; Schilder CM; de Roode ML; Deijen JB; Schagen SB
Menopause; 2015 Jan; 22(1):17-25. PubMed ID: 24977455
[TBL] [Abstract][Full Text] [Related]
14. Factors related to the experience of menopausal symptoms in women prescribed tamoxifen.
Moon Z; Hunter MS; Moss-Morris R; Hughes LD
J Psychosom Obstet Gynaecol; 2017 Sep; 38(3):226-235. PubMed ID: 27583832
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Chlebowski RT; Schottinger JE; Shi J; Chung J; Haque R
Cancer; 2015 Jul; 121(13):2147-55. PubMed ID: 25757699
[TBL] [Abstract][Full Text] [Related]
17. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
[TBL] [Abstract][Full Text] [Related]
18. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
19. Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer.
Corter AL; Broom R; Porter D; Harvey V; Findlay M
Psychooncology; 2018 Sep; 27(9):2096-2103. PubMed ID: 29776011
[TBL] [Abstract][Full Text] [Related]
20. Symptoms, symptom beliefs, and quality of life of older breast cancer survivors: a comparative study.
Heidrich SM; Egan JJ; Hengudomsub P; Randolph SM
Oncol Nurs Forum; 2006 Nov; 33(2):315-22. PubMed ID: 16518447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
